Supplemental Table S2: Adverse events possibly, probably, or definitely related to ganitumab across all 28 cycles (maximum grade per patient)

Adverse event (AE)	AE grade (Number of patients)			Total number of patients with AE
	1	2	3	
Hematologic				
Anemia	4	1	1	6
Lymphocyte count decreased	2	2		4
Neutrophil count decreased		1	1	2
Platelet count decreased	8	2		10
White blood cell decreased	3	1		4
Non-hematologic				
Abdominal pain		1		1
Alanine aminotransferase increased	2			2
Alkaline phosphatase increase	1			1
Anorexia	1			1
Aspartate aminotransferase increased	2	1		3
Bilirubin increased	1			1
Bronchopulmonary hemorrhage	1			1
Cough	2			2
Dehydration		1		1
Dyspnea	1			1
Epistaxis	1			1
Fatigue	2	1		3
Fever	1			1
Headache	2			2
Hemoptysis	1			1
Hypertension	1			1
Hyponatremia	1			1
Hypotension	1			1
Hypoxia			1	1
Nausea	1			1
Non-cardiac chest pain	1			1
Pleural effusion		1		1
Pleuritic pain	1			1
Pneumonitis			1	1
Skin ulceration	1			1
Soft tissue infection		1		1
Tachypnea	1			1
Tinnitus	1			1
Vomiting			1	1
Wheezing	1			1